Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target of $12.00. The company’s shares closed yesterday at $5.73.
McCarthy covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Daré Bioscience, and Lineage Therap. According to TipRanks, McCarthy has an average return of -30.1% and a 21.37% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Capricor Therapeutics with a $12.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $6.58 and a one-year low of $3.30. Currently, Capricor Therapeutics has an average volume of 71.52K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
Read More on CAPR:
- Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- CAPR Upcoming Earnings Report: What to Expect?
- Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
- Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
- Capricor Therapeutics appoints Gotwals to board of directors
